The pomegranate extract effect … redux

According to an article just published in the journal Prostate Cancer and Prostatic Diseases, any effect of taking pomegranate extract in delaying prostate cancer progression over time after first-line treatment may be limited. … READ MORE …

Beware over-reaction to ultrasensitive PSA doubling times

It is not exactly “new” news that PSA doubling times calculated using low levels of ultrasensitive PSA data can be very different to those calulated using standard PSA values. However, a new paper has provided some additional data on this issue. … READ MORE …

Post-surgical salvage radiation therapy and all-cause patient mortality

An article just published on-line in Cancer has demonstrated that, in a cohort of men with a median follow-up of  > 10 years, salvage radiation therapy (after first-line radical prostatectomy) reduces all-cause mortality in men with short (< 6 months) and longer (≥ 6 months) PSA doubling times at the time of initial biochemical disease progression. … READ MORE …

PSADT and the progression of prostate cancer in men on IADT

Researchers at Johns Hopkins have attempted to correlate data on PSA doubling time (PSADT) with data on prostate cancer progression in men being treated with intermittent androgen deprivation therapy (IADT) after biochemical recurrence of prostate cancer. … READ MORE …

It’s time to invest in pomegranate stocks (or orchards)!

It appears that regular use of commercially available pomegranate extract really does have a significant impact on PSA doubling time (PSADT) among men with a rising PSA but no indication of bone metastasis. … READ MORE …

Third study confirms value of PSADT as a prognostic indicator post-surgery

Earlier studies based on data from Johns Hopkins and the Center for Prostate Disease Research have shown that PSA doubling times are strongly associated with risk for metastasis, prostate cancer-specific, and overall mortality. … READ MORE …

Second study confirms data on PSADT and survival post-surgery

In 2009, at a presentation at the American Society for Clinical Oncology, Antonorakis et al. initially presented data, from the Johns Hopkins database, demonstrating the prognostic significance of PSA doubling time (PSADT) to long-term survival of men with progressive prostate cancer who were otherwise untreated after surgery. … READ MORE …